Result of AGM

24 November 2009

                                                                   GB00B39J5N63

                             Scancell Holdings Plc                             

                    (`Scancell Holdings' or the `Company')                     

                                 Result of AGM                                 

Scancell Holdings Plc, (PLUS:SCLP), the parent company of Scancell Limited
(`Scancell'), the developer of innovative therapeutic cancer vaccines,
announces that at the Annual General Meeting, held earlier today, all
resolutions were duly passed.

The Directors of the issuer accept responsibility for this announcement.

                                    -ENDS-                                     

For further information contact:

Professor Lindy Durrant      Scancell Holdings Plc  + 44 207 245 1100       
                                                                            
John Bick/Kirsty Corcoran    Hansard Group          + 44 7872 061 007/7515  
                                                    588 947                 
                                                                            
Ross Andrews                 Zeus Capital           + 44 (0)161 831 1512    

About Scancell

Scancell is developing novel therapeutic vaccines for the treatment of cancer
and infectious diseases based on its groundbreaking ImmunoBody® technology
platform. Scancell's first cancer vaccine SCIB1 is being developed for the
treatment of melanoma and will enter clinical trials in early 2010.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be
administered to a patient, stimulating an immune response. Effective cancer
vaccines need to target dendritic cells to stimulate both parts of the cellular
immune system; the helper cell system where inflammation is stimulated at the
tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system
cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they
cannot specifically target dendritic cells in vivo. Several groups have
demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing
them with tumour antigens and re-infusing them. However, this procedure is
patient specific, time consuming and expensive. Scancell has developed its
breakthrough patent protected ImmunoBody® technology to overcome these
limitations.

An ImmunoBody® is a DNA vaccine encoding a human antibody or fusion protein
engineered to express helper cell and CTL epitopes from tumour antigens
over-expressed by cancer cells. Antibodies are ideal vectors for carrying T
cell epitopes from tumour antigens as they can effectively target dendritic
cells via their Fc receptors, allowing efficient stimulation of high avidity
and high frequency helper and CTL responses.

The ImmunoBody® technology can be adapted to provide the basis for treating any
tumour type and may also be of potential utility in the development of vaccines
against hepatitis, HIV and other chronic infectious diseases.